A new publication dated September 2, 2026 reports on plasma levels of the antimicrobial peptide LL-37 in patients with obstructive sleep apnea. The study, titled "Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study," appears in the journal PloS one.
The publication is described as a clinical observational study. It examines LL-37 in the context of sleep quality among individuals with obstructive sleep apnea. LL-37 currently carries an unapproved, research-stage regulatory status, meaning it is not approved for clinical use in this or any other indication.
No results, conclusions, or efficacy data from this study have been provided beyond its title and publication details. The listing confirms only that the study was published and identifies its journal and observational design. Readers should not assume findings regarding biomarker validity, sleep outcomes, or clinical utility until the full text or additional details are reviewed directly from the source.
This brief reports solely on the fact of publication, the study title, the journal, and the date, without extending beyond the information provided. For more background on LL-37, including its general characteristics and research status, readers can consult the compound overview.